This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the STARGLO trial of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 

In this interview, Gregory shares data from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Gregory covers key outcomes, highlighting 2-year efficacy and safety data. He concludes that the data are encouraging and support using this combination as a fixed-duration, off-the-shelf therapy for patients with R/R DLBCL. 

Hosted on Acast. See acast.com/privacy for more information.